Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Replimune (REPL) EBT (2017 - 2025)

Replimune has reported EBT over the past 9 years, most recently at -$71.2 million for Q4 2025.

  • Quarterly results put EBT at -$71.2 million for Q4 2025, down 8.33% from a year ago — trailing twelve months through Dec 2025 was -$314.7 million (down 38.21% YoY), and the annual figure for FY2025 was -$246.8 million, down 14.6%.
  • EBT reached -$71.2 million in Q4 2025 per REPL's latest filing, up from -$82.1 million in the prior quarter.
  • Across five years, EBT topped out at -$22.1 million in Q1 2021 and bottomed at -$87.2 million in Q2 2025.
  • Median EBT over the past 5 years was -$50.0 million (2023), compared with a mean of -$50.8 million.
  • The largest annual shift saw EBT grew 11.93% in 2024 before it plummeted 62.13% in 2025.
  • Over 5 years, EBT stood at -$29.6 million in 2021, then crashed by 34.04% to -$39.7 million in 2022, then fell by 27.61% to -$50.6 million in 2023, then decreased by 29.85% to -$65.8 million in 2024, then decreased by 8.33% to -$71.2 million in 2025.
  • Business Quant data shows EBT for REPL at -$71.2 million in Q4 2025, -$82.1 million in Q3 2025, and -$87.2 million in Q2 2025.